in 2001, is an immune-regulatory protein in B7 family of T cell co-stimulatory molecules, which may be a new prognostic marker. 7, 8 2IgB7-H3 and 4IgB7-H3 are two isoforms in human beings.
9 B7-H3, as a very important co-stimulatory molecule, promotes T-cells proliferation and induces T-cell receptor signaling interferon production. 10 However,B7-H3 also serves as natural killer cells, T cell co inhibitor, and antigen presenting cells. 11, 12 Several subsequent studies support the viewpoint that B7-H3 inhibits the activation of T cell, and a stimulatory immunological role of B7-H3 in the area of antitumor immunity. [13] [14] [15] Some researchers suggest that the B7-H3 signaling system is one of efficient pathway in regulating lymphangiogenesis. 5, 6, 16 B7-H3 may show resistance to apoptosis via the signaling pathway of Jak2-STAT3, and facilitates vessel enlargement into the surrounding lymphatic vessels. 17 Previous epidemiological studies have showed that B7-H3 over expression was correlated with lymphatic metastasis in CRC. [18] [19] [20] [21] [22] [23] However, the results remain inconclusive. Some studies have reported that B7-H3 high expression in CRC patients are associated with lymph node metastasis and prognosis value, 18, 22, 23 while the other studies report contrary findings. 19, 20, 21 To derive the precise relationship between B7-H3 expression and clinical prognosis in CRC patients, a meta-analysis of six independent studies based on a total of 1,202 CRC patients was performed, to see the relationship between B7-H3 expression and CRC prognosis.
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METHODS
Search strategy and inclusion criteria:
A systematic literature search of Google Scholar, Embase, PubMed and two Chinese databases (Wanfang and Chinese National Knowledge Infrastructure database) were conducted by two study investigators independently for all related articles about the outcomes value of co-stimulatory molecule B7-H3 expression in CRC patients. The terms used in the research included "co-stimulatory", "B7-H3", "colorectal cancer", "CRC", "immunochemistry", "colorectal neo plasma(s)", "colorectal carcinoma", "metastasis", and "prognosis". All eligible studies and their references were browsed, and no date or language limits were applied. Inclusion and exclusion criteria: The included studies in this meta-analysis were as per the following criteria: 1. Measures B7-H3 expression in the CRC tissue with immunohistochemistry (IHC). The odds ratios (ORs) with 95% confidence interval (95% CIs) were calculated for all included studies. P value level < 0.05 was considered statistical significance. The heterogeneity was assessed by using I 2 statistics, and publication bias was tested by Egger's test and Begg's funnel plot.
RESULTS
Literature search process:
After a complete research based on the above mentioned criteria, a total of 122 suitable articles were reviewed. After reviewing the titles or abstracts, 112 articles were excluded because they were not relevant to the role of B7-H3 in CRC patients and also had insufficient data. Therefore, 10 papers were preliminarily identified for further evaluation. Among those 10 studies, six studies reported the data about the lymph node metastasis, [18] [19] [20] [21] [22] [23] including one Chinese article, 19 and three studies reported the data about the B7-H3 expression on overall survival (Fig.1) . 2022 Moreover, 1,202 cases provided lymphatic metastasis data, among which 452 cases were with metastasis and 745 cases without that, and 937 cases had positive B7-H3 expression and 265 cases were negative B7-H3 expression (Table-I (Fig.2) . Among these three studies with 933 CRC patients had the 24-month overall survival, there were no difference between study heterogeneities (I 2 =36%, P=0.21). Fixed-effects model showed the expression of B7-H3 was associated with 24-month overall survival in CRC patients (Fixed-effects, OR=0.48, 95% CI: 0.32-0.74, P<0.001) (Fig.3) . Further, two studies with fixed-effects model showed the expression of B7-H3 was associated with 72-month overall survival in CRC patients (Fixed-effects, OR = 0.61, 95% CI: 0.43-0.85, P< 0.01) (Fig.3) . Publication bias: Publication bias was evaluated by Egger's test and Begg's funnel plot. Funnel plots' shape did not appear dissymmetry, and Egger's test also showed that there was no publication bias in the association of B7-H3 expression with lymph node metastasis in CRC patients (Fig.4, P>0 .05). Since there are no more than five prognostic studies about 24-month overall survival and 72-month overall survival, these studies' publication bias was not performed. 
DISCUSSION
Colorectal cancer (CRC) is one of the most familiar malignancy types in the world, and its pathophysiology related with the interaction between individual genetic molecular background and the surrounding environmental factors. [27] [28] [29] Studies have proved that genetic modification together with get toxenobiotics bacterial toxins, diet, cigarette smoke, and drugs may increase CRC risk. 30 However, it remains unclear on the biological pathway contact life style characteristics and CRC.
Many investigators have studied the effects of the co-stimulatory molecule B7-H3 on the development of anti-apoptosis of CRC. [31] [32] [33] There is no doubt that the B7 family is an important cancer player, thus the B7-H3 study will be very promising in the field of malignancy research. High expression of B7-H3 strengthened the resistance to chemotherapeutics and anti-apoptotic ability, nevertheless knockdown of B7-H3 might enhance the sensitivity of apoptosis induced by drug. [34] [35] [36] [37] Up to now, many studies had reported that the high-expression of B7-H3 significantly correlated with lymphatic metastasis and lymphangiogenesis in CRC. 18, 22, 23 However, other reports did not prove such relationship, or opposite correlations were found. 19, 20, 21 To date, there is no agreement on relationship between highexpression of B7-H3 detected by immunochemistry and survival in CRC patients. Accurate assessment of B7-H3 over expression impact on CRC patients is needed.
In CRC, the lymphatic system is always primarily metastasis pathway and lymphatic metastasis is a key prognostic role for the disease. 38 to the limited sample size of individual studies, broad consensus on relationship between the over expression of B7-H3 and lymphatic metastasis in CRC has not reached yet. This meta-analysis including 1,202 cases from six published studies explored the relationship between the B7-H3 expression and prognosis of CRC patients. The overall results indicated that the expression of B7-H3 was not associated with lymph node metastasis. However, the B7-H3 expression in CRC patients is significantly associated with 24-month and 72-month overall survival, including three and two independent studies, respectively. The present studies' data suggest that B7-H3 expression is significantly related with the outcome of CRC patients, and those patients with B7-H3 over expression may have poorer survival rate. Our findings will be very promising for the outcome and treatment strategy of CRC, in addition to improve pathophysiology understanding.
Limitations of the study: Our results should be interpreted cautiously since there are a few limitations in the meta-analysis. Firstly, there were not enough data available from studies, and the total number of patients was only 1,202. Moreover, some clinical factors might lead to bias, such as age and/or chemotherapies plans in study. Secondly, our study might be overestimated; as there are two retrospective cohort studies included which might have higher risk of biases. 18, 20 Hence, larger and well-designed randomized controlled trial are needed to further assess the relationship between the B7-H3 over expression and CRC prognosis. Moreover, sufficient number of prospective studies are needed to further evaluate the accurate outcome effect of the B7-H3 expression in CRC patients.
This meta-analysis includes six studies which suggest that B7-H3 expression is not associated with lymphatic metastasis in CRC patients. However, the expression of B7-H3 might be an important outcome factor in CRC patients, if tested by immunochemistry. Moreover, considering the challenges relevant patient included and improvement in understanding of the pathophysiology mechanisms of B7-H3 may improve outcomes. As such further studies need to ascertain with larger Randomized Clinical Trials, widely accepted evaluation methods are necessary to expound the accurate outcome effect of the B7-H3 expression in CRC patients.
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